Description
Batefenterol is a Beta 2 adrenergic receptor agonist and also a Muscarinic receptor antagonist. It shows high affinity for hM2 (Ki = 1.4 nM), hM3 muscarinic receptors (Ki = 1.3 nM) and hβ2-adrenoceptors (Ki = 3.7 nM). Batefenterol is a hβ2-adrenoceptor agonist with EC50 value of 0.29 nM for stimulation of cAMP levels. This is 440- and 320-fold functional selectivity over hβ1- and hβ3-adrenoceptors. In Jul 2016, GlaxoSmithKline completed a phase II trial for Chronic obstructive pulmonary disease in USA, Germany and South Africa